|Podcasts|September 30, 2021
Episode 92: Digesting the GI Market
Author(s)Elaine Quilici, Miranda Schmalfuhs
Tom McCourt, CEO of Ironwood Pharmaceuticals, talks about his 30-plus years in the gastrointestinal space, including his experiences bringing top GI medicines Prilosec, Nexium, Entocort, Zelnorm, and Linzess to market.
Advertisement
Tom McCourt, CEO of Ironwood Pharmaceuticals, discusses his extensive background in gastrointestinal drug development, the current landscape of therapies, and what the future may hold for this space.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Excellergy Announces Launch with $70 Million Series A Funding Aiming to Advance Pipeline of Trifunctional Effector Cell Response Inhibitors
2
Pharma Companies Shift Towards Direct-To-Consumer Sales in US Amidst Tariff and Pricing Turmoil
3
How are the Drug Pricing Negotiations Impacting Pharma's Relationship with DC?
4
The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.
5
